Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.52 |
| ▸ | F13A1 | P00488 | 7/20 | 0.52 |
| ▸ | TGM1 | P22735 | 4/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7014107 | 0.84 | HTR2C (0.52) | TGM2F13A1TGM1 | |
| SCHEMBL5635199 | 0.83 | GAA (0.54) | GAAALDH1A1 | |
| SCHEMBL5355137 | 0.80 | HTR2C (0.52) | SMN1; SMN2TSHR | |
| SCHEMBL25221277 | 0.80 | ALDH1A1 (0.52) | MAPK1GAASMN1; SMN2ALDH1A1CYP2C9 | |
| SCHEMBL25723347 | 0.78 | TGM2 (0.53) | TGM2F13A1TGM1LMNA | |
| SCHEMBL3210642 | 0.78 | TGM2 (0.59) | TGM2F13A1TGM1SMN1; SMN2 | |
| SCHEMBL31130216 | 0.77 | BRD4 (0.46) | ALDH1A1LMNATSHR | |
| SCHEMBL31129859 | 0.77 | BRD4 (0.46) | ALDH1A1LMNATSHR | |
| SCHEMBL31539422 | 0.77 | USP2 (0.50) | SMN1; SMN2ALDH1A1LMNATSHR | |
| SCHEMBL30555215 | 0.77 | GAA (0.60) | TGM2F13A1TGM1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169788-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169788-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| US-20040220216-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2004-11-04 | — | — | US | disclosed |
| WO-2003037252-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220216-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | TGM2 2470/4885F13A1 3498/4885TGM1 1946/4885 |
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | TGM2 2470/4885F13A1 3498/4885TGM1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.